WILLIAM WOLFE: Open Payments
NPI 1831113265 · COCHRANTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 43 payments from 15 companies in 2025. Trend: 2023 $0 · 2024 $20 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $143 |
| Novo Nordisk Inc | 5 | $87 |
| PFIZER INC. | 4 | $72 |
| Verona Pharma, Inc. | 3 | $69 |
| AstraZeneca Pharmaceuticals LP | 3 | $61 |
| GlaxoSmithKline, LLC. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $55 |
| Sumitomo Pharma America, Inc. | 2 | $41 |
| Lilly USA, LLC | 2 | $37 |
| Abbott Laboratories | 2 | $32 |
Products named: VRAYLAR, Ohtuvayre, ELIQUIS, TRELEGY ELLIPTA, DUPIXENT, REXULTI, QULIPTA, AIRSUPRA.
Industry payments across PA — which companies pay providers there.
